Literature DB >> 9736335

Inhibition of caspase activity prevents anti-IgM induced apoptosis but not ceramide generation in WEHI 231 B cells.

L Chen1, T J Kim, S Pillai.   

Abstract

In apoptosis induced by Reaper in Drosophila, as well as in a number of other systems, it has been suggested that the increased synthesis of ceramide might be a consequence of the activation of the caspase/ICE (Interleukin-1beta converting enzyme) protease pathway involved in cell death, implying that ceramide generation might often be the result rather than the cause of apoptosis. WEHI 231 B cells have previously been shown to undergo apoptosis following exposure to exogenous ceramide and to produce increased amounts of ceramide in response to anti-IgM crosslinking. We show here that in WEHI 231 cells a peptide inhibitor of caspase activity blocks cell death in response to both anti-IgM and exogenous ceramide. However, the induction of ceramide synthesis by WEHI 231 cells in response to anti-IgM crosslinking is not blocked by this peptide. These results indicate that antigen receptor induced ceramide generation in WEHI 231 cells does not require caspase activation, and support the view that ceramide generation in immature B cells may be the cause rather than the consequence of activation of the caspase dependent death pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736335     DOI: 10.1016/s0161-5890(98)00044-3

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  2 in total

1.  Ceramide accumulation precedes caspase-3 activation during apoptosis of A549 human lung adenocarcinoma cells.

Authors:  Tommer Ravid; Adili Tsaba; Peter Gee; Reuven Rasooly; Edward A Medina; Tzipora Goldkorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-02-07       Impact factor: 5.464

2.  Protein phosphatase subunit G5PR is needed for inhibition of B cell receptor-induced apoptosis.

Authors:  Yan Xing; Hideya Igarashi; Xiaodan Wang; Nobuo Sakaguchi
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.